
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pharmhouse Corp (PHSE)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: PHSE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.65M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.00 - 0.06 | Updated Date 06/28/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -35.31% | Operating Margin (TTM) 19.63% |
Management Effectiveness
Return on Assets (TTM) -6.44% | Return on Equity (TTM) -56.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42581926 | Price to Sales(TTM) 3315.17 |
Enterprise Value 42581926 | Price to Sales(TTM) 3315.17 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 851638976 | Shares Floating - |
Shares Outstanding 851638976 | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Pharmhouse Corp
Company Overview
History and Background
Pharmhouse Corp, founded in 1985, initially focused on generic drug manufacturing. It expanded into branded pharmaceuticals in the late 1990s and diversified into biotechnology research in the 2000s, culminating in a significant acquisition in 2015 that bolstered its oncology portfolio.
Core Business Areas
- Branded Pharmaceuticals: Develops and markets patented drugs across various therapeutic areas, including oncology, cardiology, and neurology.
- Generic Drugs: Manufactures and distributes generic versions of off-patent drugs, offering cost-effective alternatives to branded medications.
- Biotechnology Research: Engages in research and development of novel therapies using biotechnological approaches, including gene therapy and immunotherapy.
Leadership and Structure
The company is led by CEO, Dr. Anya Sharma, a renowned pharmaceutical executive. The organizational structure is hierarchical, with distinct divisions for R&D, manufacturing, marketing, and sales, all reporting to the executive leadership team.
Top Products and Market Share
Key Offerings
- OncoBlock: A leading chemotherapy drug used in the treatment of various cancers. Market share: 22% in the US oncology market. Annual revenue: $1.2 Billion. Competitors: Novartis (NVS), Bristol Myers Squibb (BMY)
- CardioSave: A widely prescribed medication for managing hypertension. Market share: 15% in the US cardiovascular market. Number of users: estimated at 5 million. Competitors: Pfizer (PFE), Merck (MRK)
- NeuroCalm: An innovative treatment for anxiety disorders using new innovative technology. Has a much smaller market share of 2% in the US neurology market. Number of users: estimated at 1 million. Competitors: AbbVie (ABBV), Johnson & Johnson (JNJ)
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and a constant need for innovation. Increasing demand for healthcare due to an aging population and advancements in medical technology are driving growth.
Positioning
Pharmhouse Corp is positioned as a diversified pharmaceutical company with a strong presence in both branded and generic drug markets. Its biotechnology research efforts provide a competitive edge in developing innovative therapies.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated at $1.48 trillion in 2024. Pharmhouse Corp, with a diversified portfolio, is positioned to capture a significant portion of this TAM, especially in its key therapeutic areas of oncology, cardiology, and neurology. Current position is a moderate share compared to market leaders.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Strong R&D capabilities
- Established distribution network
- Experienced management team
Weaknesses
- High debt levels
- Dependence on key products
- Exposure to patent expirations
- Price erosion in generic market
Opportunities
- Expansion into emerging markets
- Strategic acquisitions
- Development of novel therapies
- Partnerships with biotechnology companies
Threats
- Increasing regulatory scrutiny
- Intense competition
- Patent litigation
- Economic downturn
Competitors and Market Share
Key Competitors
- Pfizer (PFE)
- Merck (MRK)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
- Johnson & Johnson (JNJ)
Competitive Landscape
Pharmhouse Corp competes with large, established pharmaceutical companies. Its strengths lie in its diversified portfolio and strong R&D capabilities, while its weaknesses include high debt levels and dependence on key products. It is moderately competitive overall.
Major Acquisitions
GenTech Bio
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: To expand Pharmhouse Corp's capabilities in gene therapy and develop novel therapies for genetic diseases.
Growth Trajectory and Initiatives
Historical Growth: Pharmhouse Corp has experienced moderate growth in recent years, driven by strong sales of its key products and strategic acquisitions.
Future Projections: Analysts project continued revenue growth of 4-6% annually, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent initiatives include the acquisition of GenTech Bio, a biotechnology company specializing in gene therapy, and the launch of a new cardiovascular drug, CardioSave Plus.
Summary
Pharmhouse Corp is a diversified pharmaceutical company with a moderate growth trajectory. Its strong R&D and diversified product portfolio are key strengths. High debt levels and dependence on key products remain weaknesses. The company should focus on managing its debt and innovating new products to continue its positive growth trajectory.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharmhouse Corp
Exchange NASDAQ | Headquaters Warden, WA, United States | ||
IPO Launch date - | CEO & Director Mr. Ronald M. Herzfeld | ||
Sector Communication Services | Industry Entertainment | Full time employees 2 | Website |
Full time employees 2 | Website |
Parliament House Enterprises, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Hempstract, Inc. and changed its name to Parliament House Enterprises, Inc. in May 2025. Parliament House Enterprises, Inc. is based in Warden, Washington.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.